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KEY POINTS
 Acute myocardial infarction complicated by cardiogenic shock is a deadly condition associated
with significant morbidity and mortality.
 Despite 20 years of medical advancements, early revascularization remains the sole therapy
proven to improve outcomes.
 Mechanical circulatory support devices provide a physiologically plausible mechanism of
improving outcomes by offering hemodynamic stability for revascularization and improving
end-organ perfusion. Results from well-powered randomized controlled trials, however, are
not yet available.
 Randomized controlled trials have been difficult to conduct in this patient population; until such
trials are performed, implementing shock teams and protocols has been associated with
improved outcomes in observational studies and may be considered.
 Technological advancements will lead to continued development of more mobile, smallercaliber, and more powerful mechanical circulatory support devices. Understanding the
mechanisms of action and physiologic effects of these devices, therefore, is critically important.

INTRODUCTION
Acute myocardial infarction (AMI) can result in
diastolic dysfunction and an increase in left ventricular end-diastolic pressure. If not treated
promptly, AMI can progress to systolic dysfunction and decreasing stroke volume, which can
lead to cardiogenic shock (CS). CS is a lowoutput state resulting in decreased systemic
and coronary perfusion. Decreased systemic
perfusion results in end-organ injury, whereas

decreased coronary perfusion results in further
ischemia, leading to a vicious cascade that ultimately can lead to death. The cascade of events
results in a complex neurohumoral cascade
referred to as the systemic inflammatory
response syndrome. The goals for treating AMI
and CS (AMICS), therefore, are to relieve
ischemia and improve perfusion to end organs.1
AMICS is a deadly condition associated with
significant morbidity and mortality. Patients presenting with AMICS who do not receive invasive
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therapies have less than 20% survival.2 The
Should We Emergently Revascularize Occluded
Coronaries for Cardiogenic Shock (SHOCK) trial
demonstrated improved survival in patients presenting with AMICS treated with early mechanical revascularization.3 Unfortunately, further
revascularization does not lead to further improvements in short-term survival, as was
demonstrated in the CULPRIT-SHOCK trial.4 In
the past 2 decades, there has been little
advancement made to improving outcomes
further. This is of great concern because the
prevalence of AMICS is growing in the aging
population.5 Patients frequently present with
more comorbidities and are more likely to experience cardiac arrest and CS.5
Given the high mortality associated with
AMICS despite revascularization, clinicians have
looked to other forms of therapies in the hope
of improving outcomes. Technological advancements have resulted in an increased availability
of temporary mechanical circulatory support
(MCS) devices, which can improve systemic and
coronary perfusion. These devices are reviewed
herein.

INTRA-AORTIC BALLOON PUMP
Intra-aortic balloon pump (IABP) counterpulsation is the oldest and most common form of
MCS.6–8 Since its inception in 1967, several
observational studies have suggested improved
survival with the use of IABP in patients with
AMICS9–21 (Table 1). IABPs have been demonstrated to improve systemic hemodynamics
and improve coronary perfusion, are easy to
use, and are inexpensive. Until recently, there
was 1 alternative device, venoarterial (VA)–extracorporeal membrane oxygenation (ECMO),
which was more invasive, associated with more
complications, and utilized primarily in select tertiary care centers. Therefore, the use of IABPs
was questioned infrequently for decades.
Randomized controlled trials (RCTs), however, failed to show survival benefit22–26 (Table 2).
In the Thrombolysis and Counterpulsation to
Improve Cardiogenic Shock (TACTICS) trial, 57
patients with AMICS were randomized after
thrombolytic therapy to 48 hours of IABP therapy or optimal medical therapy. The investigators found no significant difference in 6-month
mortality between the 2 groups.22 Prondzinsky
and colleagues24 randomized 45 patients with
AMICS after percutaneous coronary intervention
(PCI) to IABP therapy or optimal medical therapy. They found no difference in Acute Physiology and Chronic Health Evaluation II scores,

interleukin-6 levels, and cardiac index (CI) between the groups. In-hospital mortality also
was similar between the groups (38.6% vs
28.6%, respectively).24 The largest trial conducted evaluating the efficacy of IABP in AMICS was
the IABP-SHOCK II trial; 300 patients were randomized to IABP and 298 patients to the control
group. There was no difference in outcomes,
including secondary endpoints, such as time to
hemodynamic stabilization, length of stay in
the intensive care unit, serum lactate levels,
dose and duration of catecholamine therapy,
renal function, major bleeding, peripheral
ischemic complications, and stroke.25,26
Furthermore, numerous meta-analyses have
investigated the role of routine IABP in
AMICS.27–29 The largest analysis was performed
by Ahmad and colleagues,27 who analyzed patients presenting with AMI from 12 RCTs,
including 2123 patients, and 15 observational
studies, including 15,530 patients. They found
no difference in 30-day mortality in patients
with AMI who received IABP, regardless of the
presence (odds ratio [OR] 0.94; 95% CI, 0.69–
1.28) or absence (OR 0.98; 95% CI, 0.57–1.69)
of CS.28 As a result of these randomized trials
and meta-analyses, the European guidelines
downgraded IABP use in AMICS from a previous
class I to a class III recommendation,30 whereas
the US guidelines downgraded IABP use to a
class II recommendation.31
This review focuses on patients with AMICS.
Patients who present with CS from decompensated heart failure CS, however, differ in their
response to IABPs. Malick and colleagues32
have demonstrated that patients with decompensated heart failure CS had a 5-fold greater
cardiac output augmentation with IABP
compared with patients with AMICS.

VENOARTERIAL–EXTRACORPOREAL
MEMBRANE OXYGENATION
VA-ECMO uses a centrifugal pump and a membrane oxygenator, to provide flows of up to 3 L/
min to 7 L/min. There are few retrospective
observational studies evaluating the use of
ECMO in AMICS (Table 3). These studies
demonstrate a survival rate ranging from 47%
to 60.9% in patients who have a mean age of
54 years to 60 years.33,34 In 2010, Sheu and colleagues35 studied 115 patients with AMICS from
1993 to 2002 without ECMO support and
compared them with 219 patients with AMICS
from 2002 to 2009 with ECMO support. The
30-day mortality for patients with ECMO was
lower than the non-ECMO cohort (30.1% vs
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Table 1
Summary of observational studies of intra-aortic balloon pump in acute myocardial infarction and
cardiogenic shock
Author, Year
Published

Number of
Patients

Population

Outcomes

Moulopoulos
et al,9 1986

N 5 52
34 IABP

AMICS

10/34 patients survived
longer than a month.
15 patients in whom
IABP could not be
placed, none survived

Bengtson
et al,10 1992

N 5 200
99 IABP

AMICS

In-hospital mortality 53%
Patency of infarct-related
vessel was a predictor
of survival. No
difference between
IABP and no IABP arms

Waksman
et al,11 1993

N 5 85
20 IABP

AMICS

In-hospital and 1-y
survival was
significantly higher in
the IABP arm (46% and
38% vs 19% and 10%,
respectively; P<.001).

Stomel
et al,12 1994

N 5 64
13 thrombolytics
29 IABP
22 thrombolytics
1 IABP

AMICS

Survival improved in
thrombolytics 1 IABP
group compared with
thrombolytics or IABP
alone (68% vs 23% or
28%, respectively;
P 5 .0049).

Anderson
et al,13 1997

N 5 310
68 IABP

AMICS

Despite more adverse
events and moderate
bleeding, the IABP
cohort showed a trend
toward lower 30-d and
1-y mortality rates.

Kovack
et al,14 1997

N 5 46 patients
27 IABP

AMICS who
received
thrombolytics

Patients in the IABP arm
had significantly higher
hospital survival (93%
vs 37%, respectively;
P 5 .0002).

Brodie
et al,15 1999

N 5 1490

AMI with and
without CS

Pre-PCI IABP was
associated with lower
cardiac events in CS
(n 5 119) (14.5% vs
35.1%, respectively;
P 5 .009), in CHF or
low ejection fraction
(n 5 119) (0% vs
14.6%, respectively;
P 5 .10), and in highrisk patients (n 5 238)
(11.5% vs 21.9%,
respectively; P 5 .05).

Kumbasar
et al,16 1999

N 5 45
25 IABP

Anterior AMI who
received
thrombolytics

IABP had significantly
higher rates of
thrombolysis in
myocardial infarction
grade 3 flow (n: 11%;
44% vs n: 1%,
respectively; 5%;
P<.05). There was a
(continued on next page)
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Table 1
(continued )
Author, Year
Published

Number of
Patients

Population

Outcomes
trend toward a lower
in-hospital mortality in
the IABP group (n:
0 [0%] vs n: 3; [15%];
P 5 .08).

Sanborn
et al,17 2000

N 5 856
279 IABP,
160
IABP 1 thrombolytics
132 thrombolytics only

AMICS

Thrombolytic group had
a lower in-hospital
mortality compared
with no-thrombolytics
(54% vs 64%,
respectively; P 5 .005).
The IABP group had a
lower in-hospital
mortality compared
with no-IABP (50% vs
72%, respectively;
P<.0001).

Barron
et al,18 2001

N 5 23,180
7268 IABP

AMICS

IABP was associated with
significantly lower
mortality in the
thrombolytic group
(67% vs 49%,
respectively) but not in
PCI group (45% vs
47%, respectively).

Zeymer
et al,19 2011

N 5 653
163 IABP

AMICS

In-hospital mortality,
with and without IABP,
was 56.9% and 36.1%,
respectively. In the
multivariate analysis
the use of IABP was
not associated with
improved survival (OR
1.47; 95% CI, 0.97–
2.21; P 5 .07).

Sjauw
et al,20 2012

N 5 292
199 IABP

STEMI with
CS treated
with PCI

30-d mortality in IABP vs
no-IABP was 47% vs
28%, respectively; OR
1.67 (95% CI, 1.16–
2.39), no difference
after propensity
stratification
3-d mortality in pre-PCI
IABP vs post-PCI was
64% vs 40%,
respectively; OR of
1.56 (95% CI, 1.18–
2.08), no difference
after propensity
stratification

Zeymer
et al,21 2013

N 5 1913
487 IABP

AMICS

In-hospital mortality with
and without IABP was
43.5% and 37.4%
respectively. In
multivariate analysis,
IABP was associated
with increased
mortality (OR 1.45;
95% CI, 1.15–1.84).
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Table 2
Summary of randomized clinical trials of intra-aortic balloon pump in acute myocardial infarction and
cardiogenic shock
Author, Year Published

Number of Patients

Population

Outcomes

Ohman
et al,22 2005

57 patients

AMICS who
received
thrombolytics

No difference in 6-mo mortality
(34% for
IABP 1 thrombolytics vs 43%
for thrombolytics alone
[n 5 27]; adjusted P 5 .23)

Prondzinsky
et al,24 2010

45 patients

AMICS status
post-PCI

No difference in in-hospital
mortality, Acute Physiology
and Chronic Health
Evaluation II scores,
interleukin-6 levels, and CI at
4 d.

Thiele
et al,25 2012

598 patients

AMICS

No difference in 30-d mortality,
the time to hemodynamic
stabilization, the length of
stay in the intensive care unit,
serum lactate levels, the dose
and duration of
catecholamine therapy, renal
function, major bleeding,
peripheral ischemic
complications, and stroke

Thiele
et al,26 2018

591 patients

AMICS

No difference in 6-y mortality,
recurrent myocardial
infarction, stroke, repeat
revascularization, or
rehospitalization for cardiac
reasons

41.7%, respectively; P 5 .034). A subgroup analysis of patients in profound CS found a significant difference in mortality between groups
(39.1% in ECMO vs 72% in non-ECMO;
P 5 .008); however, in patients without profound
shock, there was no significant difference in 30day mortality between the groups (26.1% vs
21.9%, respectively; P 5 .39). Esper and colleagues36 studied 18 patients who underwent
VA-ECMO in the catheterization laboratory for
AMICS and found an in-hospital survival rate of
67% and 6-month survival of 55%. More than
one-third of patients had an IABP placed and
were on vasopressors or inotropes. Similarly,
Negi and colleagues37 studied 15 patients with
AMICS (one-third presenting with cardiac arrest)
and showed a 47% survival rate. More than 90%
of patients were on 1 to 2 inotropes at the time
of ECMO, 60% had an IABP, and the vascular
complication rate was greater than 50%. Lastly,
a recent observational study by Vallabhajosyula
and colleagues38 using the National Inpatient
Sample database evaluated 2962 patients in a
period of 14 years and demonstrated a survival

rate of 40.8%. There was a significant trend to
improved survival over time and 12% of patients
were bridged to LV assist device (LVAD) or heart
transplantation.38
There are no RCTs to date evaluating the use
of ECMO in AMICS. Two European studies,
EURO SHOCK and ECLS-SHOCK, currently are
enrolling patients. EURO-SHOCK will randomize
428 patients to ECMO or standard therapy and
will evaluate 30-day mortality as the primary
outcome; their expected study completion
date is February 2024.39 Similarly, ECLSSHOCK will enroll 420 patients with AMICS undergoing revascularization and randomize to
ECMO or medical therapy alone. The primary
outcome is 30-day mortality and the estimated
study completion date is August 2023.40

TandemHeart
TandemHeart (LivaNova, London, UK) used a
percutaneous centrifugal pump to provide flows
up to 3 L/min to 5 L/min using cannulas similar to
VA-ECMO. There are few studies assessing the
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Table 3
Major observational studies of venoarterial–extracorporeal membrane oxygenation in acute
myocardial infarction and cardiogenic shock
Observational Studies
Device (s)
Results

Author/Trial (Year)

Sample Size

Esper et al,36 2015

18

VA-ECMO

67% survival rate, very
high bleeding rates
(>90%)

Single-center
experience,
peripheral ECMO,
average length of
ECMO was 3.2 d
 2.5 d

Negi et al,37 2016

15

VA-ECMO

47% survival rates,
53% vascular
complication rates

Small sample, single
center, 33% with
cardiac arrest, 60%
with STEMI

Sheu et al,35 2010

219

VA-ECMO

60.9% survival in
ECMO vs 28%
survival in the nonECMO cohort

All patients prior to
ECMO had a IABP
and were on
dobutamine

Takayama et al, 2013

90

VA-ECMO

49% survival.

Combined AMI and
CHF patients in
shock; 23 patients
underwent
permanent LVAD
and 9 heart
transplantation.

Vallabhajosyula et al,
2019

2962

ECMO

40.8% survival

Survival improved
from 0% in 2000– to
54.9% in 2014.
Potential bias due
to administrative
database.
Multicenter, large
sample study

hemodynamic and clinical outcomes of TandemHeart in patients with AMICS (Table 4). Kar and
colleagues41 studied 80 patients with AMICS
and found that TandemHeart led to a rapid
improvement several hemodynamic measures,
including CI, systolic blood pressure, urine
output, and lactic acid levels. The mortality rates
were 40.2% and 45.3% at 30 days and 6 months,
respectively, for AMICS patients. Smith and colleagues42 analyzed 56 patients, 16 (29%) of
whom had AMICS, and found improved hemodynamics with the use of TandemHeart. They
also found that survival was significantly influenced by the indication of the TandemHeart
(23.8% in bridge to recovery vs 51% in bridge
to LVAD or surgery [P 5 .04]), and patients
who did not receive definitive therapy had
poor outcomes (13.8% survived to hospital
discharge). Further observational data are being
collected in the TandemHeart Experiences and
MEthods (THEME Registry); an ongoing

Notes

multicenter study (ClinicalTrials.gov Identifier:
NCT02326402).
Two underpowered RCTs have been conducted with the use of TandemHeart. Thiele and colleagues43 randomized 20 patients to IABP and
21 patients to TandemHeart. They found cardiac
power index and other hemodynamics measures
improved more effectively with TandemHeart;
however, complications, including severe
bleeding and limb ischemia, were more
frequent. The investigators also found no difference in 30-day mortality between groups; however, the study was underpowered to detect
these differences.43 Burkhoff and colleagues44
randomized 33 patients with AMICS to treatment with IABP or TandemHeart. They similarly
found improved hemodynamics with higher CI
and lower pulmonary capillary wedge pressure
with the use of TandemHeart; however, there
was no difference in 30-day mortality between
the groups.44
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Table 4
Major studies of TandemHeart in acute myocardial infarction and cardiogenic shock
Study,
Publication
Year

Number of
Patients

Study Type

Outcomes

Thiele
et al, 2005

41

RCT: IABP vs
TandemHeart

No difference in 30-d mortality.
TandemHeart led to improvement
in hemodynamics but was
associated with more
complications, including bleeding
and limb ischemia.

Burkhoff
et al,44 2006

33

RCT: IABP vs
TandemHeart

No difference in 30-d mortality.
TandemHeart led to improvement
in hemodynamics.

Kar
et al,41 2011

117 total,
80 with AMI,
37 with NICM

Observational:
TandemHeart in
refractory shock

30-d and 6-mo mortality rates were
40.2% and 45.3%, respectively, in
AMI, vs 32% and 35%, respectively,
in NICM.
TandemHeart led to improvement in
hemodynamics.

Smith
et al,42 2018

56 total,
16 (29%) AMI

Observational,
CS due to
advanced HF
and AMI

Survival was significantly influenced
by indication (23.8% in bridge to
recovery vs 51% in bridge to LVAD
or surgery; P 5 .04). TandemHeart
led to significant improvements in
CI and PCWP.

Schwartz
et al, 2012

76, 19 received
TandemHeart,
58% AMI

Observational

30-d mortality 63%

Abbreviations: NICM, nonischemic cardiomyopathy; PCWP, pulmonary capillary wedge pressure.

IMPELLA
Impella (Abiomed, Danvers, Massachusetts) is
continuous nonpulsatile micro-axial pump that
has an inlet area that aspirates blood from the
left ventricle and ejects it through the outlet
into the ascending aorta, at a rate up to 5.5 L/
min. Observational studies assessing the use of
Impella in CS have compared it with either medical therapy, IABP, or ECMO (Table 5). The
Impella-EUROSHOCK
registry
was
an
observational-single arm study that evaluated
120 patients with AMICS supported with an
Impella 2.5. The feasibility study demonstrated
a 64% 30-day mortality; however, it showed
feasibility of device placement and improvement
in lactate levels.45 Karatolios and colleagues46
compared Impella to medical therapy in 90 patients with cardiac arrest (27 patients were
treated with Impella) and demonstrated 65%
survival in the Impella cohort compared with
20% in the medical therapy cohort. Schrage
and colleagues47 matched patients from the
IABP-SHOCK II trial to patients supported with
an Impella device in Europe. They demonstrated

no significant difference in 30-day all-cause mortality (48.5% vs 46.4%, respectively; P 5 .64) but
did show higher rates of severe bleeding and
vascular complications in the Impella group.
The main limitation of this study was that the degree of CS was not taken into account when
matching patients. Lemor and colleagues48
analyzed AMICS patients from the National
Inpatient Sample from 2015 to 2017 who underwent PCI and had either Impella or ECMO support. Propensity-matched analysis showed
significantly lower mortality in the Impella cohort
(26.7% vs 43.3%, respectively; P 5 .02) as well as
lower ischemic stroke and vascular complication
rates. This study, however, also was limited by
the inability to match patients according to the
degree of shock. Loehn and colleagues49
showed improved survival with the use of
Impella before PCI (50% pre-PCI Impella vs
23.1% post-PCI Impella). Helgestad and colleagues50 demonstrated lower 30-day mortality
in patients receiving Impella compared with a
matched control group that underwent IABP
placement (40% vs 77.5%, respectively; P log
rank <0.001).
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Randomized Controlled Trials
Author/
Trial (Year)

Sample Size

Comparison

Results

Notes

ISAR-SHOCK51
(2008)

12 vs 13

Impella 2.5 vs
IABP

Similar 30-d
mortality in
both groups
(46% for both)

Improved CI with Impella
device

IMPRESS52
(2017)

24 vs 24

Impella CP vs
IABP

Similar 30-d
(46% vs 50%,
respectively;
P 5 .92) and
6 mo mortality
(50% for both; P 5 .9)

>90% of patients with cardiac
arrest prior device placement

Author/Trial (Year)

Observational studies
Results

Sample Size

Device (s)

82

IABP, Impella,
ECMO

30-survival was 63.4% for all
patients (62/82 supported
with Impella)

A multidisciplinary team–based
approach can improve
outcomes.

NCSI59 (2019)

171

Impella CP

72% survival with best practices
(early RHC, MCS, and PCI)

Lactate <4 and cardiac power
output >0.6 are good
predictors of survival.
Multicenter study

Utah Cardiac
Recovery Shock
Team64 (2019)

123

IABP, Impella, ECMO

54.5% survival (for the entire
cohort—IABP, Impella,
ECMO)

33.3% of patients supported
with Impella. AMICS in 61%

Schrage
et al,49 2019

237 matched
patients from
IABP-SHOCK trial

Impella CP vs IABP

No difference in survival (48.5%
vs 46.4%, respectively;
P 5 .64)

Selection bias and unable to
compare degree of shock
between patients

EUROSHOCK45
(2013)

120

Impella 2.5

64% 30-d mortality

Impella is feasible and reduced
lactate levels

Karatolios
et al,46 2018

90

Impella CP vs
medical
therapy

65% survival in Impella cohort
vs 20% with medical therapy
(27/90 with Impella support)

All patients had cardiac arrest.
Single-center study

INOVA

60

(2019)

Notes

Lemor et al
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Table 5
Summary of randomized controlled trials and observational studies for Impella

5730 vs 560
(450
propensity
matched)

Impella CP vs
ECMO

Propensity matched: in-hospital
mortality rates were 26.7% vs
43.3%, respectively.

Potential bias due to
administrative database.
Multicenter, large sample
study

Loehn
et al,49 2020

73

Impella CP

50% survival for Impella Pre-PCI
vs 23.1% for Impella post-PCI

More patients in the Impella
post-PCI group had cardiac
arrest, although younger
patients in the Impella prePCI group with higher
percentage of left main
disease.

Helgestad
et al,50 2020

903 (279
with MCS)

Impella CP vs IABP

Lower 30-d mortality compared
with matched control group
(40% vs 77.5%, respectively;
P log rank <0.001).

Matched cohort included 40
patients in each group.

Abbreviation: RHC, right heart cath.

Mechanical Circulatory Support
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Two underpowered RCTs have been conducted evaluating Impella in AMICS. Both compared
Impella versus IABP in a small sample of patients. The ISAR-SHOCK trial randomized 25 patients to either Impella 2.5 or IABP and
demonstrated safety and feasibility to use
Impella 2.5 in AMICS. Patients treated with
Impella had similar 30-day mortality when
compared with IABP (46%); however, Impella
did provide better hemodynamic support.51
The IMPella versus IABP Reduces mortality in
STEMI patients treated with primary PCI in Severe cardiogenic SHOCK (IMPRESS) trial was a
randomized, prospective, open-label, multicenter trial that enrolled 48 patients with AMICS
and randomized patients to an Impella CP or
IABP.52 The investigators aimed to enroll more
than 100 patients but the trial was prematurely
stopped due to poor enrollment. Overall, the results showed similar mortality rates for both cohorts (46% for Impella and 50% for IABP; P 5 .9).

RIGHT VENTRICULAR FAILURE
Acute right coronary artery occlusion proximal
to the right ventricular (RV) branches, or less
commonly left circumflex artery occlusion, often
results in RV ischemia. RV ischemia can lead to
depressed RV systolic function decreasing transpulmonary flow and left ventricular filling. This
can result in diminished preload and cardiac
output. The severity of the hemodynamic
compromise in patients with RV failure is related
to the extent of RV ischemia, left ventricular
function, and ventricular interdependence.53 Patients with RV dysfunction are prone to bradyarrhythmias, which can further decrease cardiac
output. Hemodynamic compromise from RV failure, therefore, should be treated first with volume resuscitation, restoration of physiologic
rhythm or pacing, and inotropic agents. Patients
with persistent RV failure can be considered for
RV MCS devices.
In patients with left ventricular dysfunction,
increased left ventricular pressures and pulmonary venous pressures lead to increased RV
afterload, which further decreases RV output.
Lala and colleagues54 analyzed patients from
the SHOCK trial, which recruited primarily patients with left ventricular failure and found
that the prevalence of RV failure (ie, biventricular
failure) was 38%. They defined RV failure using
hemodynamic parameters: central venous pressure greater than 10 mm Hg, central venous
pressure/pulmonary capillary wedge pressure
greater than 0.63, pulmonary artery pulsatility index less than 2, and RV stroke work index less

than 450 g*m/m2. Using similar definitions, Basir
and colleagues demonstrated similar findings in
the National Cardiogenic Shock Initiative (NCSI)
and identified these patients as having increased
mortality compared with those with isolated left
ventricular failure.
VA-ECMO is a powerful RV assist device
(RVAD), and, in the setting of concomitant left
sided failure, may be the preferred modality of
MCS, because it provides biventricular support.
Unfortunately, data on its use specifically for
RV failure in the setting of AMICS are limited.
The Impella RP is a percutaneous microaxial
pump designed to support the RV. There are
few data demonstrating the impact of Impella
RP on outcomes in patients with RV dysfunction
(Table 6). Cheung and colleagues55 studied 18
patients, 39% of whom had AMI and found
that Impella RP led to improvements in hemodynamic measures and reported a 30-day survival
rate of 72% and a 1-year survival rate of 50%.
The RECOVER RIGHT study included 30 patients
with RV failure refractory to medical therapy.
The investigators found that patients had
improvement in hemodynamics with the use of
an Impella RP. Overall, 73.3% of patients survived to 30 days.56
TandemHeart–RVADs (TH-RVADs) use an
extracorporeal centrifugal flow pump and 2
venous cannulas to deliver blood from the right
atrium (RA) to the main PA via bilateral femoral
venous cannulation. A 21F inflow cannula is
placed in the RA and a second 21F outflow cannula is inserted into the main PA. Usually, the
outflow cannula is placed in the main PA via
the right femoral vein, and the inflow cannula is
placed in the RA via the left femoral vein. If the
distance from femoral vein to fifth intercostal
space exceeds 58 cm or femoral access cannot
be used, the internal jugular venous access can
be utilized. There also is a ProtekDuo (LivaNova,
London, UK) dual-lumen cannula, which can be
placed in the right internal jugular vein. It contains 2 lumens within one 29F or 31F cannula,
taking blood from RA to the extracorporeal
pump then delivering it to the PA. There are
few data on the use of TH-RVAD on outcomes
(see Table 5). Kapur and colleagues57 retrospectively studied outcomes in 46 patients with RV
failure who received a TH-RVAD, of whom 21 patients were cannulated percutaneously. THRVAD implantation was associated with a significant decrease in RA pressure and a significant
increase in CI. In-hospital mortality was 33% in
patients with AMI. In another study by Kapur
and colleagues,58 9 patients, 6 of whom had
AMI, had improved hemodynamics when
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Table 6
Major studies assessing acute mechanical circulatory support in right ventricular dysfunction
Study, Year
Published

Device

Number of
Patients

Cheung et al,
2014

Impella RP

Anderson et al,56
2015

Population

Outcomes

18

39% AMI, other
etiologies
include posttransplant,
myocarditis

30-d survival 72%
1-y survival 50%
Hemodynamic
effects:
increased CI,
decreased RA
pressure

Impella RP

30

40% AMI, others
include postLVAD

30-d survival
73.3%
Hemodynamic
effects:
increased CI,
decreased RA
pressure

Kapur et al,57 2013

TH-RVAD

46

25% AMI, others
include post–
cardiac surgery,
transplant,
myocarditis

In-hospital
mortality 57%
Hemodynamic
effects:
increased CI,
MAP and PA,
decreased RA
pressure

Kapur et al,58 2011

TH-RVAD

9

66.7% AMI, others
include post–
cardiac surgery

In-hospital
mortality 44%
Hemodynamic
effects:
increased RV
stroke volume,
MAP and PA,
decreased RA
pressure

Truby et al,65 2015

VA-ECMO

179

26% AMI, others
include post–
cardiac surgery

In-hospital
mortality 38.6%
Hemodynamic
effects:
decreased RA
and mean PA
pressure

55

Abbreviations: MAP, mean arterial pressure; PA, pulmonary artery.

treated with TH-RVAD, with an in-hospital mortality rate of 44%.

SHOCK PROTOCOLS AND TEAMS
Shock protocols allow for a uniform treatment
strategy in an effort to provide patients, nurses,
and clinicians a systematic pathway of care,59
although shock teams provide a diverse set of
options that can be catered to the individual patient, taking into account operator and institutional expertise.60 This concept is best

exemplified in the work of the NCSI. Investigators involved in the study began by reviewing
outcomes data in AMICS and forming best practices, which were put together into a shock protocol. The study was limited to evaluating
outcomes in patients with AMICS and not other
shock phenotypes. The study also used inclusion
and exclusion criteria similar to previous RCTs in
an effort to compare with prior work.
The shock protocol was piloted in metro
Detroit and named the Detroit Cardiogenic
Shock Initiative.61 A 41-patient pilot study found
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Fig. 1. The 50-year mortality trend in AMI complicated by CS. Over 50 years, mortality in AMI with CS has
increased steadily from approximately 80% to close to 30%. (Adapted from Goldberg RJ, Spencer FA, Gore
JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital
death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based
perspective. Circulation. 2009;119(9):1211-1219; with permission.)

the protocol could be used across selected centers and was associated with high survival
compared with historical studies and local outcomes. The study then was expanded and
renamed the NCSI. The goal was to see if the
shock protocol could be reproduced in centers
across the United States. In total, greater than
60 sites were recruited with a goal of enrolling
400 patients. The NCSI is the first contemporary
study to evaluate outcomes of a shock protocol.
The best practices included in the protocol are1
to identify AMICS early and treat patients in the

catheterization laboratory (early is defined
as <90 minutes to 120 minutes of diagnosis
and prior to escalating use of inotropes)2; placement of Impella prior to PCI, because PCI can
result in reperfusion injury, distal embolization,
and transient cessation of coronary perfusion
with balloon inflations and stents, which are better tolerated with MCS; and3 use of pulmonary
artery catheters to assess patients underlying
hemodynamic state and to guide further therapy, including escalation of MCS, identification
of RV failure, and weaning. The study has

Fig. 2. Key components of a CS
team. Using a shock team and protocol has been associated with
improved outcomes in numerous
observational studies. Early triage,
prompt identification, and rapid delivery of MCS based on a patient’s
physiologic state are steps important in CS management. A multidisciplinary team–based approach,
which includes interventional cardiology, advanced heart failure, cardiac surgery, and critical care, has
proved efficient in improving outcomes without delaying care and it
is highly recommended in clinical
practice. Early identification of shock starts in the emergency department and the decision to send a patient to
the catheterization laboratory should not be delayed, which highlights the importance of good communication between the emergency department and the cardiology team. Escalation for additional left ventricle or RV support as
well as transfer to a tertiary care center (if needed) should be discussed early by the multidisciplinary team.
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enrolled more than 300 patients with AMICS and
has demonstrated survival to hospital discharge
greater than 70%.62,63

SUMMARY
AMI complicated by CS is a deadly condition
associated with significant morbidity and mortality (Fig. 1). Despite 20 years of medical advancements, early revascularization remains the sole
therapy proved to improve outcomes. MCS devices provide a physiologically plausible mechanism of improving outcomes by offering
hemodynamic stability for revascularization and
improving end-organ perfusion. Results from
well-powered RCTs, however, are not yet available. RCTs have been difficult to conduct in
this patient population; until such trials are performed, implementing shock teams and protocols has been associated with improved
outcomes in observational studies and may be
considered (Fig. 2). Technological advancements will lead to continued development of
more mobile, smaller-caliber, and more powerful MCS devices. Understanding the mechanism
of action and physiologic effects of these devices, therefore, is critically important.
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